OQROGet OQRO Pro
Politician trade (House)

Ultragenyx Pharmaceutical (RARE)Rep. Gilbert Cisneros (CA31) disclosed a purchase $1K–$15K

Rep. Gilbert Cisneros (CA31) disclosed a purchase of Ultragenyx Pharmaceutical in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
35 days
Disclosure lag
Traded
Mar 3, 2026
Disclosed
Apr 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 12, 2026Company filing · Form 8-K · ResultsReported its results
  2. Feb 12, 2026Company filing · Form 8-K · Results, RestructuringAnnounced job cuts, closures or a restructuring, and reported its results“On February 12, 2026, the Company began implementation of a strategic restructuring plan to reduce expenses (the “Restructuring”). As part of the Restructuring, the Company is implementing a 10% workforce reduction of approximately 130 employees across the Company (the “RIF”).”
  3. Feb 18, 2026CongressDisclosed purchase of RARE — reported range $1,001 - $15,000
  4. Mar 3, 2026 · this disclosureCongressDisclosed purchase of RARE — reported range $1,001 - $15,000

What came next

  1. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  2. May 14, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As reported below, at its Annual Meeting of Stockholders (the “ Annual Meeting ”) on May 14, 2026, the stockholders of Ultragenyx Pharmaceutical Inc. (“ Ultragenyx ” or the “ Company ”) approved the Third Amended and Restated 2023 Incentive Plan (the “ Third A&R 2023 Plan ”).”
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Ultragenyx Pharmaceutical

For Ultragenyx Pharmaceutical, OQRO holds 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RARE page.

Other recent filings by Rep. Gilbert Cisneros (CA31)

The full history of Rep. Gilbert Cisneros (CA31) is on the profile page.

How this filing works

Other disclosures at Ultragenyx Pharmaceutical

Everything OQRO holds on this company is on its RARE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data